Technical Analysis for IMCR - Immunocore Holdings plc

Grade Last Price % Change Price Change
D 60.49 -0.56% -0.34
IMCR closed down 0.56 percent on Monday, March 18, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
Multiple of Ten Bullish Other -0.56%
Inside Day Range Contraction -0.56%
Oversold Stochastic Weakness -0.56%
New Downtrend Bearish 0.58%
200 DMA Support Bullish 0.58%
Multiple of Ten Bullish Other 0.58%
Gapped Down Weakness 0.58%
Oversold Stochastic Weakness 0.58%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 11 hours ago
Rose Above Previous Day's High about 11 hours ago
Down 2 % about 13 hours ago
Down 1% about 13 hours ago
Possible Inside Day 3 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunocore Holdings plc Description

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Infectious Diseases Autoimmune Disease Oncology Breast Cancer Virotherapy Immunotherapies Small Cell Lung Cancer Solid Tumor Cancers Oncolytics Biotech Treatment Of Autoimmune Disease Chronic Hepatitis B Virus Immunocore Pelareorep

Is IMCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 76.98
52 Week Low 42.23
Average Volume 515,952
200-Day Moving Average 59.49
50-Day Moving Average 69.43
20-Day Moving Average 65.42
10-Day Moving Average 61.91
Average True Range 2.50
RSI (14) 30.07
ADX 27.8
+DI 11.07
-DI 24.91
Chandelier Exit (Long, 3 ATRs) 65.65
Chandelier Exit (Short, 3 ATRs) 66.87
Upper Bollinger Bands 73.12
Lower Bollinger Band 57.72
Percent B (%b) 0.18
BandWidth 23.53
MACD Line -2.67
MACD Signal Line -2.15
MACD Histogram -0.519
Fundamentals Value
Market Cap 2.99 Billion
Num Shares 49.4 Million
EPS -1.42
Price-to-Earnings (P/E) Ratio -42.60
Price-to-Sales 19.11
Price-to-Book 10.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.21
Resistance 3 (R3) 63.20 62.28 62.76
Resistance 2 (R2) 62.28 61.59 62.29 62.61
Resistance 1 (R1) 61.39 61.16 60.93 61.40 62.46
Pivot Point 60.47 60.47 60.24 60.47 60.47
Support 1 (S1) 59.57 59.78 59.11 59.58 58.52
Support 2 (S2) 58.65 59.35 58.66 58.37
Support 3 (S3) 57.76 58.65 58.22
Support 4 (S4) 57.77